Research programme: histone deacetylase inhibitors - Roche/Takeda San Diego

Drug Profile

Research programme: histone deacetylase inhibitors - Roche/Takeda San Diego

Alternative Names: 383994; Histone deacetylase inhibitors research programme - Roche/Syrrx; Research programme: HDAC inhibitors - Roche/Syrrx

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Roche; Takeda San Diego
  • Class
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 01 Mar 2005 Syrrx has been acquired by Takeda
  • 17 May 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top